Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for EXEL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 248.88M
March 31, 2026 253.70M
December 31, 2025 262.48M
September 30, 2025 268.10M
June 30, 2025 270.13M
March 31, 2025 275.03M
December 31, 2024 281.73M
September 30, 2024 285.78M
June 30, 2024 285.22M
March 31, 2024 295.03M
December 31, 2023 302.79M
September 30, 2023 310.97M
June 30, 2023 320.25M
March 31, 2023 324.98M
December 31, 2022 323.95M
September 30, 2022 322.54M
June 30, 2022 321.80M
March 31, 2022 320.27M
December 31, 2021 318.84M
September 30, 2021 316.30M
June 30, 2021 314.82M
March 31, 2021 313.26M
December 31, 2020 311.63M
September 30, 2020 309.40M
June 30, 2020 308.89M
Date Value
March 31, 2020 305.78M
December 31, 2019 304.83M
September 30, 2019 303.78M
June 30, 2019 302.78M
March 31, 2019 301.52M
December 31, 2018 299.88M
September 30, 2018 298.88M
June 30, 2018 297.89M
March 31, 2018 296.69M
December 31, 2017 296.21M
September 30, 2017 295.70M
June 30, 2017 293.73M
March 31, 2017 292.30M
December 31, 2016 289.92M
September 30, 2016 286.12M
June 30, 2016 230.24M
March 31, 2016 228.68M
December 31, 2015 227.96M
September 30, 2015 226.15M
June 30, 2015 196.38M
March 31, 2015 196.02M
December 31, 2014 195.90M
September 30, 2014 195.18M
June 30, 2014 195.09M
March 31, 2014 194.65M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 133.73M
BioMarin Pharmaceutical, Inc. 193.54M
Cytokinetics, Inc. 138.76M
Emergent BioSolutions, Inc. 51.30M
Gilead Sciences, Inc. 1.241B